首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1944563

siRNA藥物市場報告：趨勢、預測和競爭分析（至2031年）

siRNA Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2026年02月17日 | 出版商:

Lucintel | 英文 213 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

由於醫院、研究機構以及製藥和生物技術公司蘊藏著巨大的機遇，全球siRNA藥物市場前景廣闊。預計2025年至2031年，全球siRNA藥物市場將以19.4%的複合年成長率成長。推動該市場發展的關鍵因素包括遺傳疾病的增加、對個人化醫療需求的成長以及對RNA治療方法的日益關注。

Lucintel預測，在預測期內，奈米顆粒將成為所有遞送方式中成長率最高的。
按最終用途分類，醫院預計將呈現最高的成長率。
從地區來看，預計北美在預測期內將出現最高的成長率。

siRNA藥物市場的新趨勢

受基因靜默技術進步、標靶治療需求成長以及對遺傳疾病認知加深的推動，siRNA藥物市場正經歷快速成長。在研究進展的驅動下，該市場以創新、策略合作和在多個治療領域的應用拓展為特徵。這些發展正在改變個人化醫療的面貌，為過去難以治療的疾病帶來新的希望。以下關鍵趨勢突顯了塑造這個充滿活力的市場的重大變革，並反映了為未來成長和改善患者療效鋪平道路的技術、監管和商業性進步。

加大研發投入：生技公司、製藥公司和政府機構不斷增加的資金投入正在加速siRNA技術的發展。這些投入支持新型遞送系統的發現，並有助於提高siRNA分子的穩定性和特異性。隨著研發力道的增加，更有效、更安全的siRNA治療方法正在湧現，縮短了上市時間，並擴大了潛在藥物的研發管線。這一趨勢凸顯了克服當前限制、最大限度發揮siRNA技術治療潛力的決心。
遞送技術的進步：開發創新遞送系統，例如脂質奈米顆粒、偶聯物和病毒載體，對於有效的siRNA療法至關重要。這些進步提高了細胞攝取、穩定性以及標靶遞送能力，同時最大限度地減少了脫靶效應和毒性。增強的藥物遞送方法使siRNA藥物能夠到達以前難以到達的組織和器官，從而拓寬了其治療應用範圍。這一趨勢對於克服siRNA療法面臨的主要挑戰之一至關重要，有助於提高臨床成功率和市場接受度。
拓展至新的治療領域：siRNA藥物最初主要應用於遺傳性疾病和癌症，如今正被探索用於感染疾病、罕見疾病、發炎性疾病等多種疾病。這種多元化發展得益於siRNA技術的多功能性，它能夠沉默與多種病理相關的特定基因。隨著新適應症的發現，市場不斷擴大，吸引了更多投資和監管機構的注意。這一趨勢正使siRNA療法更加全面和個人化，從而滿足眾多疾病領域尚未滿足的醫療需求。
策略聯盟與合作日益增加：生技公司、製藥公司和學術機構之間的合作日益普遍。這些夥伴關係有助於知識共用、資源整合，並加速產品研發進程。授權協議和合資企業也十分常見，有助於企業順利通過法規核准，有效率地實現產品商業化。這些合作對於克服技術挑戰、加速創新siRNA療法的上市至關重要，最終將促進市場成長，提升市場競爭力。
不斷變化的監管環境：監管機構正在製定基於siRNA治療方法的具體指導方針，這正在影響打入市場策略。更清晰的監管路徑和核准流程正在降低不確定性，並促進投資。然而，與安全性、給藥方式和脫靶效應相關的監管挑戰仍然存在。開發商和監管機構之間持續的對話對於建立既能促進創新又能確保安全性的標準至關重要。這種不斷變化的環境正在塑造市場擴張的步伐，並影響著該領域企業的策略規劃。

總而言之，這些趨勢正透過刺激創新、拓展治療可能性和簡化研發流程，共同重塑siRNA藥物市場。這些趨勢正引領市場走向更有效、更具標靶性和個人化的療法，最終改善患者預後並開啟新的商業性機會。隨著這些發展的持續推進，siRNA市場有望迎來顯著成長，並在醫療保健產業中發揮越來越重要的作用。

siRNA藥物市場的最新趨勢

受基因靜默技術進步、生物技術研究投入增加以及標靶治療需求上升的推動，siRNA藥物市場正經歷顯著成長。隨著精準醫療日益重要，基於siRNA的治療方法為包括遺傳性疾病、癌症和病毒感染疾病在內的多種疾病提供了極具前景的解決方案。近期技術創新和策略合作加速了siRNA藥物的開發平臺，提高了其療效和可及性。這些進展正在重塑個人化醫療的模式，為製藥公司創造新的機遇，同時也拓展了siRNA技術在全球的治療潛力。

技術進步：改進的遞送系統，如脂質奈米顆粒和綴合物，提高了siRNA的穩定性和靶向精確度，從而提高了療效並減少了副作用，進而擴大了臨床應用範圍。
策略聯盟：領先的生物技術和製藥公司正在結盟，以加速研發、共用專業知識和簡化監管核准，加速siRNA藥物的商業化。
監管核准：近期基於 siRNA 的治療方法（例如用於治療遺傳性轉甲狀腺素類澱粉沉積症樣變性的療法）獲得核准，驗證了該技術的有效性，並提振了投資者的信心，從而刺激了進一步的創新和市場准入。
拓展治療領域：研究人員正在探索 siRNA 在遺傳疾病以外的潛在應用，包括癌症、感染疾病和罕見疾病，從而使市場多元化並擴大收入來源。
投資和資金籌措：創業投資和政府機構不斷增加的投資正在刺激創新，支持臨床試驗，並擴大生產流程，所有這些都在推動市場成長。

這些進展正透過提高藥物療效、拓展治療選擇和吸引投資，對siRNA藥物市場產生重大影響。市場競爭日益激烈，創新不斷湧現，進而縮短了藥物研發週期，並提高了病患的用藥可近性。總而言之，這些趨勢使siRNA技術成為未來個人化醫療的基石，有望改善患者健康狀況並帶來巨大的商業性機會。

The future of the global siRNA drug market looks promising with opportunities in the hospital, research institute, and pharmaceutical & biotechnology company markets. The global siRNA drug market is expected to grow with a CAGR of 19.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of genetic disorders, the rising demand for personalized medicine, and the growing focus on RNA-based therapies.

Lucintel forecasts that, within the delivery method category, nanoparticle is expected to witness the highest growth over the forecast period.
Within the end use category, hospital is expected to witness the highest growth.
In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the siRNA Drug Market

The siRNA drug market is experiencing rapid growth driven by advances in gene silencing technology, increasing demand for targeted therapies, and a deeper understanding of genetic diseases. As research progresses, the market is characterized by innovation, strategic collaborations, and expanding applications across various therapeutic areas. These developments are transforming the landscape of personalized medicine and offering new hope for previously untreatable conditions. The following key trends highlight the major shifts shaping this dynamic market, reflecting technological, regulatory, and commercial advancements that are paving the way for future growth and improved patient outcomes.

Growing Investment in Research and Development: Increased funding from biotech firms, pharmaceutical companies, and government agencies is accelerating siRNA technology development. This investment supports the discovery of novel delivery systems, enhanced stability, and specificity of siRNA molecules. As R&D efforts intensify, more effective and safe siRNA-based therapies are emerging, reducing time-to-market and expanding the pipeline of potential drugs. This trend underscores a commitment to overcoming current limitations and unlocking the full therapeutic potential of siRNA technology.
Advances in Delivery Technologies: The development of innovative delivery systems such as lipid nanoparticles, conjugates, and viral vectors is crucial for effective siRNA therapy. These advancements improve cellular uptake, stability, and targeted delivery, minimizing off-target effects and toxicity. Enhanced delivery methods are enabling siRNA drugs to reach previously inaccessible tissues and organs, broadening their therapeutic applications. This trend is pivotal in overcoming one of the main challenges in siRNA therapeutics, thereby increasing clinical success rates and market adoption.
Expansion into New Therapeutic Areas: Initially focused on genetic disorders and cancer, siRNA drugs are now being explored for infectious diseases, rare diseases, and inflammatory conditions. This diversification is driven by the versatility of siRNA technology to silence specific genes involved in various pathologies. As new indications are identified, the market is expanding, attracting more investment and regulatory interest. This trend is making siRNA therapies more comprehensive and personalized, addressing unmet medical needs across a broader spectrum of diseases.
Increasing Strategic Collaborations and Partnerships: Collaborations between biotech firms, pharmaceutical companies, and academic institutions are becoming more prevalent. These partnerships facilitate knowledge sharing, resource pooling, and accelerated development timelines. Licensing agreements and joint ventures are also common, helping to navigate regulatory pathways and commercialize products efficiently. Such collaborations are vital for overcoming technical challenges and bringing innovative siRNA therapies to market faster, ultimately boosting market growth and competitiveness.
Evolving Regulatory Landscape: Regulatory agencies are developing specific guidelines for siRNA-based therapies, which influence market entry strategies. Clearer regulatory pathways and approval processes are reducing uncertainties and encouraging investment. However, regulatory challenges related to safety, delivery, and off-target effects remain. Ongoing dialogue between developers and regulators is essential to establish standards that ensure safety while fostering innovation. This evolving landscape is shaping the pace of market expansion and influencing strategic planning for companies operating in this space.

In summary, these trends are collectively reshaping the siRNA drug market by fostering innovation, expanding therapeutic possibilities, and streamlining development processes. They are driving the market toward more effective, targeted, and personalized treatments, ultimately improving patient outcomes and opening new commercial opportunities. As these developments continue, the siRNA market is poised for significant growth and increased impact in the healthcare industry.

Recent Developments in the siRNA Drug Market

The siRNA drug market has experienced significant growth driven by advancements in gene silencing technologies, increasing investment in biotech research, and a rising demand for targeted therapies. As precision medicine gains prominence, the development of siRNA-based treatments offers promising solutions for various diseases, including genetic disorders, cancers, and viral infections. Recent innovations and strategic collaborations have accelerated the pipeline of siRNA drugs, making them more effective and accessible. These developments are reshaping the landscape of personalized medicine, fostering new opportunities for pharmaceutical companies, and expanding the therapeutic potential of siRNA technology globally.

Technological Advancements: Enhanced delivery systems such as lipid nanoparticles and conjugates have improved siRNA stability and targeting accuracy, leading to higher efficacy and reduced side effects, thus broadening the scope of clinical applications.
Strategic Collaborations: Major biotech firms and pharmaceutical companies are forming partnerships to accelerate research and development, share expertise, and streamline regulatory approvals, which is speeding up the commercialization of siRNA drugs.
Regulatory Approvals: Recent approvals of siRNA-based therapies, such as those for hereditary transthyretin amyloidosis, have validated the technology and increased investor confidence, encouraging further innovation and market entry.
Expanding Therapeutic Areas: Researchers are exploring siRNA applications beyond genetic disorders, including cancer, infectious diseases, and rare conditions, thereby diversifying the market and increasing revenue streams.
Investment and Funding: Rising investments from venture capitalists and government agencies are fueling innovation, supporting clinical trials, and facilitating the scaling of manufacturing processes, which collectively boost market growth.

These developments are significantly impacting the siRNA drug market by enhancing drug efficacy, expanding therapeutic options, and attracting increased investment. The market is becoming more competitive and innovative, leading to faster drug development cycles and broader patient access. Overall, these trends are positioning siRNA technology as a cornerstone of future personalized medicine, promising improved health outcomes and substantial commercial opportunities.

Strategic Growth Opportunities in the siRNA Drug Market

The siRNA drug market is experiencing rapid growth driven by advancements in gene silencing technology and increasing demand for targeted therapies. As precision medicine gains prominence, the market is expanding across various applications, including oncology, infectious diseases, genetic disorders, respiratory diseases, and rare diseases. These applications are unlocking new therapeutic possibilities, attracting investments, and fostering innovation. The evolving landscape presents significant opportunities for pharmaceutical companies, biotech firms, and research institutions to develop novel siRNA-based solutions. Understanding these key growth opportunities is essential for stakeholders aiming to capitalize on the markets potential and address unmet medical needs effectively.

Targeted Cancer Therapies: siRNA enables precise silencing of oncogenes, improving treatment efficacy and reducing side effects, thus transforming cancer management.
Antiviral and Antimicrobial Agents: siRNA offers a promising approach to combat resistant pathogens by silencing essential viral or microbial genes, enhancing infectious disease control.
Personalized Medicine: siRNA facilitates gene-specific interventions for hereditary conditions, providing tailored treatments that improve patient outcomes.
Asthma and COPD Management: siRNA-based therapies can modulate inflammatory pathways, offering new options for chronic respiratory conditions.
Orphan Drug Development: siRNA provides a novel therapeutic avenue for rare genetic disorders, addressing unmet needs and expanding market opportunities.

In summary, these growth opportunities are significantly impacting the siRNA drug market by broadening its application scope, fostering innovation, and attracting investments. They are driving the development of targeted, effective therapies that meet diverse medical needs, ultimately accelerating market expansion and improving patient care outcomes.

siRNA Drug Market Driver and Challenges

The siRNA drug market is influenced by a complex interplay of technological advancements, economic factors, and regulatory frameworks. Rapid innovations in gene-silencing technologies have opened new therapeutic avenues, while economic considerations such as R&D investments and healthcare spending impact market growth. Additionally, regulatory policies governing drug approval and safety standards significantly shape market dynamics. These factors collectively determine the pace of market expansion, the development of new treatments, and the challenges faced by industry stakeholders. Understanding these drivers and challenges is essential for strategic planning and sustainable growth in the evolving landscape of siRNA therapeutics.

The factors responsible for driving the siRNA drug market include:-

Technological Innovation: The continuous development of more efficient delivery systems and enhanced stability of siRNA molecules has significantly propelled market growth. Advances such as lipid nanoparticles and conjugation techniques improve targeting accuracy and reduce side effects, making siRNA drugs more viable for clinical use. These innovations enable the development of personalized medicine and expand the scope of treatable diseases, including genetic disorders and cancers. As research progresses, the pipeline of potential therapies grows, attracting investments and fostering market expansion.
Rising Prevalence of Chronic Diseases: The increasing incidence of chronic and genetic diseases such as cancer, hepatitis, and rare genetic disorders drives demand for targeted therapies like siRNA drugs. These conditions often lack effective treatments, creating a significant need for innovative solutions. The ability of siRNA to selectively silence disease-causing genes offers a promising therapeutic approach, encouraging pharmaceutical companies to invest in research and development. This trend is expected to sustain market growth as unmet medical needs continue to rise globally.
Regulatory Approvals and Support: Favorable regulatory pathways and approvals for siRNA-based therapies have accelerated market penetration. Regulatory agencies are increasingly recognizing the potential of RNA interference technology, providing guidelines that facilitate clinical trials and commercialization. Supportive policies, grants, and collaborations between biotech firms and regulatory bodies further streamline the development process. These factors reduce time-to-market and boost investor confidence, thereby fueling market expansion.
Strategic Collaborations and Investments: Partnerships between biotech firms, pharmaceutical companies, and academic institutions have been instrumental in advancing siRNA research. These collaborations facilitate resource sharing, accelerate clinical development, and enhance technological capabilities. Increased venture capital investments and funding initiatives also support innovation and commercialization efforts. Such strategic alliances help overcome technical challenges and expand the pipeline of siRNA drugs, contributing to sustained market growth.

The challenges facing this siRNA drug market include:-

Delivery and Stability Issues: One of the primary challenges in the siRNA drug market is ensuring efficient delivery to target cells while maintaining stability in the bloodstream. siRNA molecules are prone to degradation by nucleases, and their large size hampers cellular uptake. Developing safe, effective delivery systems such as lipid nanoparticles or conjugates adds complexity and cost to drug development. Overcoming these hurdles is crucial for clinical success and widespread adoption, but technical limitations continue to impede rapid progress.
Off-Target Effects and Safety Concerns: siRNA therapies may inadvertently silence unintended genes, leading to off-target effects that can cause adverse reactions. Ensuring specificity and minimizing immune responses remain significant challenges. Regulatory agencies demand rigorous safety data, which prolongs development timelines and increases costs. Addressing these safety concerns is vital for gaining regulatory approval and market acceptance, but the complexity of gene regulation complicates this process.
High Development Costs and Lengthy Approval Processes: The cost of developing siRNA drugs is substantial due to extensive research, clinical trials, and regulatory compliance. The lengthy approval process delays market entry and increases financial risks for companies. Limited manufacturing scalability and high production costs further hinder commercialization. These economic barriers restrict the entry of smaller players and slow overall market growth, despite the promising therapeutic potential.

In summary, the siRNA drug market is driven by technological innovations, increasing disease prevalence, regulatory support, and strategic collaborations. However, challenges such as delivery issues, safety concerns, and high development costs pose significant hurdles. These factors collectively influence the pace of market growth, requiring ongoing innovation and regulatory navigation. Overcoming these challenges will be essential for realizing the full potential of siRNA therapeutics and achieving sustainable market expansion in the coming years.

List of siRNA Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies siRNA drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the siRNA drug companies profiled in this report include-

Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Silence Therapeutics plc
Dicerna Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Benitec Biopharma Ltd.
Marina Biotech, Inc.
Quark Pharmaceuticals, Inc.
RXi Pharmaceuticals Corporation

siRNA Drug Market by Segment

The study includes a forecast for the global siRNA drug market by delivery method, application, end use, and region.

siRNA Drug Market by Delivery Method [Value from 2019 to 2031]:

Nanoparticles
Lipid-based
Polymer-based
Others

siRNA Drug Market by Application [Value from 2019 to 2031]:

Oncology
Cardiovascular
Respiratory
Neurological
Infectious Diseases
Others

siRNA Drug Market by End Use [Value from 2019 to 2031]:

Hospitals
Research Institutes
Pharmaceutical & Biotechnology Companies
Others

siRNA Drug Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the siRNA Drug Market

The siRNA drug market has experienced significant growth driven by advancements in gene therapy, increasing investment in biotech research, and a rising demand for targeted treatments for various diseases. As precision medicine gains traction, countries are focusing on innovative delivery systems, regulatory approvals, and expanding clinical trials. The competitive landscape is evolving with collaborations between biotech firms and pharmaceutical giants, aiming to accelerate the development and commercialization of siRNA-based therapies. These developments reflect a global shift towards personalized medicine, with each country contributing uniquely based on its research capabilities, regulatory environment, and healthcare priorities.

United States: The US leads in siRNA drug development with numerous clinical trials underway, driven by major biotech companies like Alnylam and Moderna. Regulatory agencies have approved several siRNA therapies, which have boosted market confidence. Investment in research and partnerships with academic institutions is accelerating innovation, especially in rare diseases and genetic disorders. The US also sees increased commercialization efforts and expanding manufacturing capabilities to meet rising demand.
China: China is rapidly advancing in siRNA research, supported by government initiatives and increased funding for biotech startups. Several local companies are entering clinical trials, focusing on cancer and infectious diseases. The country is also developing its manufacturing infrastructure to reduce reliance on imports and improve cost competitiveness. Regulatory frameworks are evolving to facilitate faster approval processes, encouraging domestic innovation.
Germany: Germany emphasizes precision medicine and has a strong biotech research ecosystem. Several startups and established firms are conducting clinical trials for siRNA therapies targeting neurological and metabolic diseases. The country benefits from collaborations within the European Union, facilitating access to funding and regulatory support. Germany is also investing in advanced delivery technologies to enhance siRNA efficacy and safety.
India: India is emerging as a key player in siRNA research, with increasing government and private sector investments. Several research institutions are conducting early-stage trials, focusing on infectious diseases and cancer. The country aims to develop affordable therapies by building local manufacturing capacity and reducing costs. Regulatory reforms are underway to streamline approval processes and promote innovation in gene-based therapies.
Japan: Japan is focusing on integrating siRNA therapies into its healthcare system, with significant investments in research and development. The country has established collaborations between academia and industry to accelerate clinical trials, especially for rare and genetic diseases. Japan is also advancing delivery technologies and exploring combination therapies to improve treatment outcomes. Regulatory pathways are being refined to support faster market entry for innovative siRNA drugs.

Features of the Global siRNA Drug Market

Market Size Estimates: siRNA drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: siRNA drug market size by delivery method, application, end use, and region in terms of value ($B).
Regional Analysis: siRNA drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different delivery method, application, end use, and regions for the siRNA drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the siRNA drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the siRNA drug market by delivery method (nanoparticles, lipid-based, polymer-based, and others), application (oncology, cardiovascular, respiratory, neurological, infectious diseases, and others), end use (hospitals, research institutes, pharmaceutical & biotechnology companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global siRNA Drug Market by Delivery Method

4.1 Overview
4.2 Attractiveness Analysis by Delivery Method
4.3 Nanoparticles : Trends and Forecast (2019-2031)
4.4 Lipid-based : Trends and Forecast (2019-2031)
4.5 Polymer-based : Trends and Forecast (2019-2031)
4.6 Others : Trends and Forecast (2019-2031)

5. Global siRNA Drug Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Oncology : Trends and Forecast (2019-2031)
5.4 Cardiovascular : Trends and Forecast (2019-2031)
5.5 Respiratory : Trends and Forecast (2019-2031)
5.6 Neurological : Trends and Forecast (2019-2031)
5.7 Infectious Diseases : Trends and Forecast (2019-2031)
5.8 Others : Trends and Forecast (2019-2031)

6. Global siRNA Drug Market by End Use

6.1 Overview
6.2 Attractiveness Analysis by End Use
6.3 Hospitals : Trends and Forecast (2019-2031)
6.4 Research Institutes : Trends and Forecast (2019-2031)
6.5 Pharmaceutical & Biotechnology Companies : Trends and Forecast (2019-2031)
6.6 Others : Trends and Forecast (2019-2031)

7. Regional Analysis

7.1 Overview
7.2 Global siRNA Drug Market by Region

8. North American siRNA Drug Market

8.1 Overview
8.2 North American siRNA Drug Market by Delivery Method
8.3 North American siRNA Drug Market by End Use
8.4 The United States siRNA Drug Market
8.5 Canadian siRNA Drug Market
8.6 Mexican siRNA Drug Market

9. European siRNA Drug Market

9.1 Overview
9.2 European siRNA Drug Market by Delivery Method
9.3 European siRNA Drug Market by End Use
9.4 German siRNA Drug Market
9.5 French siRNA Drug Market
9.6 Italian siRNA Drug Market
9.7 Spanish siRNA Drug Market
9.8 The United Kingdom siRNA Drug Market

10. APAC siRNA Drug Market

10.1 Overview
10.2 APAC siRNA Drug Market by Delivery Method
10.3 APAC siRNA Drug Market by End Use
10.4 Chinese siRNA Drug Market
10.5 Indian siRNA Drug Market
10.6 Japanese siRNA Drug Market
10.7 South Korean siRNA Drug Market
10.8 Indonesian siRNA Drug Market

11. ROW siRNA Drug Market

11.1 Overview
11.2 ROW siRNA Drug Market by Delivery Method
11.3 ROW siRNA Drug Market by End Use
11.4 Middle Eastern siRNA Drug Market
11.5 South American siRNA Drug Market
11.6 African siRNA Drug Market

12. Competitor Analysis

12.1 Product Portfolio Analysis
12.2 Operational Integration
12.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

13.1 Value Chain Analysis
13.2 Growth Opportunity Analysis
- 13.2.1 Growth Opportunity by Delivery Method
- 13.2.2 Growth Opportunity by Application
- 13.2.3 Growth Opportunity by End Use
13.3 Emerging Trends in the Global siRNA Drug Market
13.4 Strategic Analysis
- 13.4.1 New Product Development
- 13.4.2 Certification and Licensing
- 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

14.1 Competitive Analysis Overview
14.2 Alnylam Pharmaceuticals, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.3 Arrowhead Pharmaceuticals, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.4 Silence Therapeutics plc
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.5 Dicerna Pharmaceuticals, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.6 Ionis Pharmaceuticals, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.7 Arbutus Biopharma Corporation
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.8 Benitec Biopharma Ltd.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.9 Marina Biotech, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.10 Quark Pharmaceuticals, Inc.
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
14.11 RXi Pharmaceuticals Corporation
- Company Overview
- siRNA Drug Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

15. Appendix

15.1 List of Figures
15.2 List of Tables
15.3 Research Methodology
15.4 Disclaimer
15.5 Copyright
15.6 Abbreviations and Technical Units
15.7 About Us
15.8 Contact Us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

siRNA藥物：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

siRNA醫藥品的全球市場:實際成果與預測(2023年～2029年)

FAQ

siRNA藥物市場報告：趨勢、預測和競爭分析（至2031年）

siRNA Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

目錄

第1章執行摘要

第2章市場概覽

第3章：市場趨勢與預測分析

4. 全球siRNA藥物市場依給藥方式分類

第5章全球siRNA藥物市場（依應用分類）

6. 全球siRNA藥物市場依最終用途分類

第7章區域分析

第7章：北美siRNA藥物市場

第8章：歐洲siRNA藥物市場

9. 亞太地區siRNA藥物市場

10. 世界其他地區（ROW）siRNA藥物市場

第12章競爭分析

第13章：機會與策略分析

第14章價值鏈中主要企業的概況

第15章附錄

siRNA Drug Market by Delivery Method [Value from 2019 to 2031]:

siRNA Drug Market by Application [Value from 2019 to 2031]:

siRNA Drug Market by End Use [Value from 2019 to 2031]:

siRNA Drug Market by Region [Value from 2019 to 2031]:

This report answers following 11 key questions: